Russell Investments Group Ltd. Reduces Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Russell Investments Group Ltd. trimmed its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 12.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 96,395 shares of the specialty pharmaceutical company's stock after selling 13,152 shares during the quarter. Russell Investments Group Ltd. owned 0.17% of Supernus Pharmaceuticals worth $3,486,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Envestnet Asset Management Inc. boosted its stake in Supernus Pharmaceuticals by 6.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock valued at $2,169,000 after purchasing an additional 3,495 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Supernus Pharmaceuticals by 14.4% during the fourth quarter. Wells Fargo & Company MN now owns 63,237 shares of the specialty pharmaceutical company's stock valued at $2,287,000 after buying an additional 7,961 shares during the last quarter. Villanova Investment Management Co LLC grew its holdings in Supernus Pharmaceuticals by 10.7% during the fourth quarter. Villanova Investment Management Co LLC now owns 57,032 shares of the specialty pharmaceutical company's stock worth $2,062,000 after buying an additional 5,496 shares in the last quarter. Headlands Technologies LLC raised its position in Supernus Pharmaceuticals by 203.0% in the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock valued at $55,000 after buying an additional 1,015 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Supernus Pharmaceuticals by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock valued at $54,633,000 after acquiring an additional 28,517 shares in the last quarter.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the firm's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Padmanabh P. Bhatt sold 700 shares of the business's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the sale, the vice president now owns 10,149 shares in the company, valued at approximately $402,103.38. The trade was a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on SUPN. Cantor Fitzgerald reiterated a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 17th.

Supernus Pharmaceuticals Stock Up 1.8 %

SUPN stock traded up $0.55 during midday trading on Tuesday, hitting $30.84. The company's stock had a trading volume of 354,293 shares, compared to its average volume of 494,139. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of 28.82 and a beta of 0.90. The stock's 50-day moving average price is $32.41 and its 200 day moving average price is $35.01. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.